Alyeska Investment Group L.P. Trims Holdings in Becton, Dickinson and Company (BDX)

Alyeska Investment Group L.P. lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 44.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 398,394 shares of the medical instruments supplier’s stock after selling 320,256 shares during the quarter. Alyeska Investment Group L.P. owned approximately 0.18% of Becton, Dickinson and worth $78,065,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Almanack Investment Partners LLC. purchased a new stake in shares of Becton, Dickinson and during the first quarter worth approximately $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in shares of Becton, Dickinson and by 55.8% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares during the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Becton, Dickinson and by 8.1% during the second quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock worth $133,000 after purchasing an additional 51 shares during the last quarter. Harfst & Associates Inc. raised its stake in shares of Becton, Dickinson and by 46.4% during the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 221 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd raised its stake in shares of Becton, Dickinson and by 82.8% during the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after purchasing an additional 338 shares during the last quarter. Institutional investors own 88.46% of the company’s stock.

Becton, Dickinson and Company (BDX) opened at $217.81 on Friday. Becton, Dickinson and Company has a twelve month low of $161.50 and a twelve month high of $229.68. The firm has a market capitalization of $49,660.00, a price-to-earnings ratio of 23.07, a P/E/G ratio of 1.71 and a beta of 1.06. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. Becton, Dickinson and’s revenue was down 2.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.12 earnings per share. analysts expect that Becton, Dickinson and Company will post 10.63 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be issued a $0.75 dividend. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date is Thursday, December 7th. This represents a $3.00 annualized dividend and a yield of 1.38%. Becton, Dickinson and’s dividend payout ratio is 62.80%.

BDX has been the topic of a number of recent analyst reports. Cowen reaffirmed a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. Barclays reaffirmed an “equal weight” rating and set a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. BidaskClub raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Wells Fargo & Company reaffirmed a “positive” rating and set a $235.00 price objective (up previously from $225.00) on shares of Becton, Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $230.00 price objective (up previously from $210.00) on shares of Becton, Dickinson and in a report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $217.08.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.40% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Alyeska Investment Group L.P. Trims Holdings in Becton, Dickinson and Company (BDX)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/12/08/alyeska-investment-group-l-p-trims-holdings-in-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply